Experiment 1044039
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | LEV,LM: POSADA JR,JG:. (1983). ACLARUBICIN: STATUS OF PHASE 1 AND 2 STUDIES IN THE UNITED STATES.. 1(1) |
| Amount utilized | |
| Compound isolated | |
| Disease | THE TITLE COMPOUND HAS COMPLETED PHASE I STUDIES IN THE UNITED STATES. THE RECOMMENDED PHASE II DOSAGE RANGES FROM 80-120 MG/SQ M EVERY 3 WEEKS. A REVIEW OF PHASE I AND PHASE II STUDIES OF THE COMPOUND SHOWS THAT ACTIVITY HAS BEEN SEEN IN ACUTE LEUKEMIA, MULTIPLE MYELOMA AND OVARIAN CANCER. TOXIC EFFECTS ARE NAUSEA AND VOMITING AND DOSE-LIMITING MYELOSUPPRESSION. CARDIOTOXICITY HAS NOT BEEN A PROBLEM AND IS CONFINED MOSTLY TO THE PRESENCE OF ASYMPTOMATIC ECG ABNORMALITIES. |
| Dose amount | 80.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |